EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The CARMUCI Study Design: A Double‐Blind, Cross‐Over Sham‐Controlled Trial of Indoor Air Purification in People With Cystic Fibrosis and Primary Ciliary Dyskinesia

Maria G Kakkoura iD, Pinelopi Anagnostopoulou iD, Panayiotis Kouis iD, Antonis Michanikou iD, Panagiotis Bargiotas, Tonia Adamides, Phivos Ioannou, Stavroula F Louka, Marina Neophytou iD, Georgios K Nikolopoulos, Chrysanthi Skevaki, Petros Koutrakis und 1 weitere

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71514 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Maria G Kakkoura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Cyprus, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Air Filters, Air Pollution, Indoor, Ciliary Motility Disorders, Cystic Fibrosis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H2020 Marie Sklodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with cystic fibrosis (pwCF) and primary ciliary dyskinesia (pwPCD) are particularly vulnerable to the harmful effects of air pollution due to the impairment of mucociliary clearance (MCC). Despite growing evidence supporting the use of indoor air purification in common lung conditions, its role in CF and PCD remains unexplored.

Methods

The Clean Air for Rare MCC dIsorders (CARMUCI) study is a randomized, double‐blind, cross‐over, sham‐controlled trial aiming to evaluate the impact of indoor air purification on the respiratory health of pwCF and pwPCD (children and adults) in Cyprus. Sixty‐two participants will receive two 3‐month intervention periods using identical‐looking air purifiers: one 3‐month period with active filtration via high‐efficiency filters and one 3‐month period with a sham unit. Primary outcome will be a mean difference of at least 10% change in lung clearance index, and secondary outcomes will include spirometry, pulmonary exacerbations, inflammatory biomarkers, and health‐related quality of life. Exposure to indoor particulate matter (PM) will be continuously monitored using device operation logs and wearable activity trackers.

Results

By August 2025, 24 pwCF and 26 pwPCD (20 females, age: 31 [16.1] years) have been enrolled. CARMUCI continues enrollment and will start data collection in September 2025. Results are expected to provide novel evidence on the efficacy of air purification in reducing indoor PM exposure and improving respiratory outcomes in people with chronic MCC disorders.

Conclusion

CARMUCI trial first results are expected in late‐2027 and may inform future clinical guidelines and environmental health strategies for managing rare MCC disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Air FiltersAir Pollution, IndoorCiliary Motility DisordersCystic FibrosisKartagener SyndromeAdolescentAdultChildFemaleHumansMaleYoung AdultCross-Over StudiesDouble-Blind MethodMucociliary ClearanceParticulate MatterQuality of LifeResearch DesignRandomized Controlled Trials as Topic

Substanzen

Particulate Matter

Autor:innen und Institutionen

  • Medical School, University of Cyprus, Nicosia, Cyprus.
  • Pulmonology Clinic, Nicosia General Hospital, Nicosia, Cyprus.
  • Pediatric Pulmonology Unit, Hospital 'Archbishop Makarios III', Nicosia, Cyprus.
  • Biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Nicosia, Cyprus.
  • Department of Civil & Environmental Engineering, University of Cyprus, Nicosia, Cyprus.
  • Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps Universität Marburg, German Center for Lung Research (DZL), Marburg, Germany.

ORCID-Profile: Maria G Kakkoura, Pinelopi Anagnostopoulou, Panayiotis Kouis, Antonis Michanikou, Marina Neophytou, Panayiotis K Yiallouros

Förderung

  • H2020 Marie Sklodowska-Curie Actions

Zitieren

APA

Kakkoura, M. G., Anagnostopoulou, P., Kouis, P., Michanikou, A., Bargiotas, P., Adamides, T., Ioannou, P., Louka, S. F., Neophytou, M., Nikolopoulos, G. K., Skevaki, C., Koutrakis, P., & Yiallouros, P. K. (2026). The CARMUCI Study Design: A Double‐Blind, Cross‐Over Sham‐Controlled Trial of Indoor Air Purification in People With Cystic Fibrosis and Primary Ciliary Dyskinesia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71514

Vancouver

Kakkoura MG, Anagnostopoulou P, Kouis P, Michanikou A, Bargiotas P, Adamides T, et al. The CARMUCI Study Design: A Double‐Blind, Cross‐Over Sham‐Controlled Trial of Indoor Air Purification in People With Cystic Fibrosis and Primary Ciliary Dyskinesia. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71514

BibTeX
@article{Kakkoura2026,
  author = {Kakkoura, Maria G and Anagnostopoulou, Pinelopi and Kouis, Panayiotis and Michanikou, Antonis and Bargiotas, Panagiotis and Adamides, Tonia and Ioannou, Phivos and Louka, Stavroula F and Neophytou, Marina and Nikolopoulos, Georgios K and Skevaki, Chrysanthi and Koutrakis, Petros and Yiallouros, Panayiotis K},
  title = {The CARMUCI Study Design: A Double‐Blind, Cross‐Over Sham‐Controlled Trial of Indoor Air Purification in People With Cystic Fibrosis and Primary Ciliary Dyskinesia},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71514}
}
Kostenlos starten →